ImageneBio, Inc. (IMA) stock
IMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.45−0.27 (-7.26%)
Close on Nov 12, 2026Market cap $39.16MP/E –Yield –
ImageneBio operating margin
Operating margin is operating income as a percentage of revenue.
ImageneBio's operating margin for the twelve months ending Dec 31, 2025 was -6056.4%. For fiscal 2025 it was -6056.4%, against -1057.1% the year before. The highest annual figure on record is -110.2% in fiscal 2021.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -6056.4% | −4999.2 |
| FY2024 | Dec 31, 2024 | -1057.1% | −233.8 |
| FY2023 | Dec 31, 2023 | -823.3% | −369.3 |
| FY2022 | Dec 31, 2022 | -454.0% | −343.8 |
| FY2021 | Dec 31, 2021 | -110.2% | +374.0 |
| FY2020 | Dec 31, 2020 | -484.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | -749.4% | +173.3 |
| Q3 FY2024 | Sep 30, 2024 | -58.2% | +233.8 |
| Q4 FY2023 | Dec 31, 2023 | -3324.4% | −3047.1 |
| Q3 FY2023 | Sep 30, 2023 | -1645.8% | −1366.6 |
| Q2 FY2023 | Jun 30, 2023 | -922.7% | +4561.9 |
| Q1 FY2023 | Mar 31, 2023 | -292.0% | +209.2 |
| Q4 FY2022 | Dec 31, 2022 | -277.3% | −291.1 |
| Q3 FY2022 | Sep 30, 2022 | -279.2% | +108.4 |
| Q2 FY2022 | Jun 30, 2022 | -5484.6% | −5127.1 |
| Q1 FY2022 | Mar 31, 2022 | -501.2% | −221.4 |
| Q4 FY2021 | Dec 31, 2021 | 13.8% | +40095.3 |
| Q3 FY2021 | Sep 30, 2021 | -387.7% | −167.3 |
| Q2 FY2021 | Jun 30, 2021 | -357.5% | −192.9 |
| Q1 FY2021 | Mar 31, 2021 | -279.8% | −57.4 |
| Q4 FY2020 | Dec 31, 2020 | -40081.5% | – |
| Q3 FY2020 | Sep 30, 2020 | -220.3% | – |
| Q2 FY2020 | Jun 30, 2020 | -164.6% | – |
| Q1 FY2020 | Mar 31, 2020 | -222.4% | – |
See a number that looks wrong?